• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

作者信息

Gornstein Erica L, Sandefur Sara, Chung Jon H, Gay Laurie M, Holmes Oliver, Erlich Rachel L, Soman Salil, Martin L Katherine, Rose Andrea V, Stephens Philip J, Ross Jeffrey S, Miller Vincent A, Ali Siraj M, Blau Sibel

机构信息

Foundation Medicine, Inc, Cambridge, MA.

Northwest Medical Specialties, Puyallup, WA.

出版信息

Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.

DOI:10.1016/j.clbc.2017.12.010
PMID:29325860
Abstract
摘要

相似文献

1
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.通过组织和液体活检的基因组分析检测到的与雌激素受体阳性乳腺癌中奥拉帕尼获得性耐药相关的BRCA2回复突变
Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.
2
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.胚系BRCA2突变的转移性去势抵抗性前列腺癌对奥拉帕利的反应：一例报告
BMC Med Genet. 2018 Oct 17;19(1):185. doi: 10.1186/s12881-018-0703-9.
3
Olaparib for the treatment of breast cancer.奥拉帕利用于治疗乳腺癌。
Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21.
4
Resurrection of PARP Inhibitors in Breast Cancer.PARP 抑制剂在乳腺癌中的复兴。
J Natl Compr Canc Netw. 2018 Sep;16(9):1150-1156. doi: 10.6004/jnccn.2018.7031.
5
Identification of Somatically Acquired Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.通过 cfDNA 分析鉴定转移性乳腺癌患者的体细胞获得性突变。
Clin Cancer Res. 2020 Sep 15;26(18):4852-4862. doi: 10.1158/1078-0432.CCR-20-0638. Epub 2020 Jun 22.
6
Olaparib Keeps Hereditary Breast Tumors in Check.奥拉帕利可抑制遗传性乳腺癌。
Cancer Discov. 2017 Aug;7(8):OF10. doi: 10.1158/2159-8290.CD-NB2017-085. Epub 2017 Jun 5.
7
Olaparib for the treatment of breast cancer.奥拉帕利治疗乳腺癌。
Expert Rev Anticancer Ther. 2018 Jun;18(6):519-530. doi: 10.1080/14737140.2018.1458613. Epub 2018 Mar 30.
8
Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.奥拉帕利片治疗种系 BRCA 突变转移性乳腺癌。
Expert Rev Clin Pharmacol. 2018 Sep;11(9):833-839. doi: 10.1080/17512433.2018.1513321. Epub 2018 Aug 30.
9
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of Reversion Mutations Associated with Resistance to PARP Inhibitors.循环无细胞 DNA 分析鉴定与 PARP 抑制剂耐药相关的回复突变的多克隆异质性。
Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.
10
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.PARP抑制剂AZD2281（奥拉帕尼）可诱导BRCA1和BRCA2突变的乳腺癌细胞发生自噬/线粒体自噬。
Int J Oncol. 2015 Jul;47(1):262-8. doi: 10.3892/ijo.2015.3003. Epub 2015 May 12.

引用本文的文献

1
Multi-omics Characterization of Acquired Olaparib Resistance in BRCA1 and BRCA2 Mutant Breast Cancer Cell Lines.BRCA1和BRCA2突变乳腺癌细胞系中获得性奥拉帕尼耐药性的多组学特征分析
Mol Cell Proteomics. 2025 Jul 14;24(8):101034. doi: 10.1016/j.mcpro.2025.101034.
2
reversion mutation confers resistance to olaparib in breast cancer.回复突变赋予乳腺癌对奥拉帕尼的抗性。
Clin Case Rep. 2023 Jun 23;11(6):e7537. doi: 10.1002/ccr3.7537. eCollection 2023 Jun.
3
Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment.
PARP1抑制剂耐药机制及其对癌症治疗的影响。
NAR Cancer. 2022 Dec 22;4(4):zcac042. doi: 10.1093/narcan/zcac042. eCollection 2022 Dec.
4
Flavonoids Targeting the mTOR Signaling Cascades in Cancer: A Potential Crosstalk in Anti-Breast Cancer Therapy.黄酮类化合物靶向癌症中的 mTOR 信号级联：抗乳腺癌治疗中的潜在串扰。
Oxid Med Cell Longev. 2022 Jun 27;2022:4831833. doi: 10.1155/2022/4831833. eCollection 2022.
5
Interaction mechanism of olaparib binding to human serum albumin investigated with NMR relaxation data and computational methods.利用核磁共振弛豫数据和计算方法研究奥拉帕利与人血清白蛋白的相互作用机制。
RSC Adv. 2018 Sep 10;8(55):31555-31563. doi: 10.1039/c8ra05330h. eCollection 2018 Sep 5.
6
Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy.新型双重靶向溴结构域蛋白 4/酪蛋白激酶 2 抑制剂的发现可诱导三阴性乳腺癌治疗中的细胞凋亡和自噬相关细胞死亡。
J Med Chem. 2021 Dec 23;64(24):18025-18053. doi: 10.1021/acs.jmedchem.1c01382. Epub 2021 Dec 15.
7
Genomic alteration profiles of lung cancer and their relationship to clinical features and prognosis value using individualized genetic testing.利用个体化基因检测分析肺癌的基因组改变图谱及其与临床特征的关系和预后价值。
J Thorac Dis. 2021 Aug;13(8):5007-5015. doi: 10.21037/jtd-21-1031.
8
Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.提高PARP抑制剂在乳腺癌中治疗指数的最新进展
Cancers (Basel). 2021 Aug 17;13(16):4132. doi: 10.3390/cancers13164132.
9
Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer.泛素 E2 酶 UBE2W 在乳腺癌中的预后价值及其与肿瘤浸润免疫细胞的相关性。
BMC Cancer. 2021 Apr 30;21(1):479. doi: 10.1186/s12885-021-08234-4.
10
Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.乳腺癌体细胞突变图谱：沙特阿拉伯患者靶向治疗的新机遇
Oncotarget. 2021 Mar 30;12(7):686-697. doi: 10.18632/oncotarget.27909.